SciELO - Scientific Electronic Library Online

 
vol.22 issue12Metformin in the treatment of type 2 diabetes in overweighted or obese patientsTroponin I in patients with pulmonary thromboembolism author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Anales de Medicina Interna

Print version ISSN 0212-7199

Abstract

VAZQUEZ FUERTES, L. et al. Inducción de tolerancia en la hipersensibilidad a mesalazina (5-ASA). An. Med. Interna (Madrid) [online]. 2005, vol.22, n.12, pp.586-588. ISSN 0212-7199.

Mesalazine is a derivative of 5-aminosalicylic acid (5-ASA), which is useful in the treatment of intestinal inflammatory disease. Sulfasalazine is formed by two parts, sulfapyridine and 5-ASA, the latter being the active part of the molecule. The new preparatives derived from 5-ASA were developed in an attempt to avoid the traditionally associated side effects to sulfapyridine, although they are still observed and new effects appear. We present two cases. The first is a man diagnosed of inflammatory intestinal disease, with background of two previous reactions of urticaria and angioedema after acetyl salicylic acid, who presented urticaria after taking mesalazine. The second one had generalized urticaria after three months of initiating treatment with mesalazine. Given the need for treatment in both cases, a desensitization protocol to mesalazine was made. It was developed in 17 days in our service. Tolerance to that drug to therapeutic doses is reached. When faced with patients with hypersensitivity to different drugs, that are necessary to treat their disease, "desensitization" regimes, that assure good tolerance, can be made.

Keywords : 5-aminosalicylic acid (5-ASA); Desensitization; Hypersensitivity; Mesalazine.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License